Related Experiment Video

Updated: Oct 4, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery

S C Barbaux1, S Blankenberg, H J Rupprecht

  • 1Institut National de la Santé et de la Recherche Médicale (INSERM) U525, Paris, France.

Arteriosclerosis, Thrombosis, and Vascular Biology
|October 13, 2001
PubMed

Insights

Soluble P-selectin levels are linked to coronary artery disease (CAD) risk, influenced by gene variations. This study found a complex, age-dependent relationship between P-selectin and CAD, suggesting varied roles in the disease process.

Area of Science:

  • Cardiovascular biology
  • Genetics
  • Molecular medicine

Background:

  • P-selectin is a cell adhesion molecule involved in leukocyte interactions.
  • Elevated soluble P-selectin levels are observed in cardiovascular disorders.
  • P-selectin gene polymorphisms may influence soluble P-selectin levels and cardiovascular disease risk.

Purpose of the Study:

  • To investigate the association between P-selectin gene polymorphisms and serum soluble P-selectin levels.
  • To examine the relationship between serum soluble P-selectin levels and coronary artery disease (CAD).
  • To explore potential age-dependent effects of soluble P-selectin on CAD.

Main Methods:

  • Serum soluble P-selectin levels were measured.
  • Three P-selectin gene polymorphisms (C-2123G, A-1969G, Thr715Pro) were genotyped.
  • A cohort of 869 CAD patients and 334 healthy controls were analyzed.

Main Results:

  • The three P-selectin polymorphisms were strongly associated with serum P-selectin levels, explaining significant variability.
  • Genotype distributions did not differ between CAD patients and controls.
  • Soluble P-selectin levels showed an age-dependent association with CAD: higher in younger patients (<55 years) and lower in older patients (>65 years) compared to controls.

Conclusions:

  • P-selectin gene polymorphisms significantly correlate with serum soluble P-selectin levels.
  • A complex, age-dependent relationship exists between soluble P-selectin levels and coronary artery disease.
  • Soluble P-selectin may play multifaceted roles in the atherothrombotic process.

Related Concept Videos

Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...